While Gilead is often thought of as king in the HIV space and is leading the race for successful interferon-free hepatitis C treatment with some astounding cure rates in clinical trials, its recent announcement that it will acquire YM BioSciences highlights a lesser-known direction for the company: its oncology pipeline. In this video, Motley Fool health care analyst David Williamson discusses what the acquisition means for Gilead and its aspirations in the oncology field.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


The article 1 Buyout Bolstering Big Biotech originally appeared on Fool.com.

Brenton Flynn has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid T he Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Understanding Stock Market Indexes

What does it mean when people say "the market is up 2%"?

View Course »

Investing in Emerging Markets

Learn to invest in a globalized world.

View Course »

Add a Comment

*0 / 3000 Character Maximum